Governor’s Task Force on Alzheimer’s Prevention and Preparedness

By Commentary, In the News

Dear friends of UCI MIND, Last week, Maria Shriver and the Governor’s Task Force on Alzheimer’s Prevention and Preparedness presented a report describing their 10 recommendations to Governor Gavin Newsom. Click here to view the report. The Governor was extremely receptive to the recommendations. We anticipate movement in the coming months to years on these important initiatives to improve the lives of Californians living with dementia and their families and to increase Alzheimer’s awareness, risk reduction education, and research. We would like to thank the many UCI MIND stakeholders who participated in the Task Force listening session as part of…

Read More

Aducanumab Still Needs to Prove Itself, Researchers Say

By Carousel Slider, Commentary, In the News

Will Biogen’s aducanumab become the first drug approved to slow progression of Alzheimer’s disease? UCI MIND faculty member and chair of UCI Statistics, Dr. Daniel Gillen, and other experts comment on ALZFORUM. Related posts: OC Register: Former California First Lady Maria Shriver gives UC Irvine gender-related research on Alzheimer’s disease another boost … Could I have immunity to the COVID-19 virus? As COVID-19 cases spread across the state and nation, demand is growing for blood tests to identify people who may have been exposed to the novel coronavirus and developed antibodies to it. Such antibodies may mean these individuals have…

Read More

Holidays during COVID-19

By Commentary, COVID-19, Participants

Contributed by UCI MIND Nurse Practitioner, Catherine McAdams-Ortiz, MSN, RN, A/GNP Have you noticed the Holiday decorations popping up at shopping malls already? Yes, the Holiday Season is upon us. This year, due to the COVID-19 pandemic, we all need to carefully plan our social gatherings, meals, and guests in our homes. Hopefully, you will find some helpful hints here so you can safely navigate all the Holidays you will celebrate this year.   The very best gift you can give yourself, your loved ones and your friends is to make sure you get your flu vaccine as soon as possible….

Read More

New insights from study of people age 90 and above

By Carousel Slider, Commentary, In the News

Related posts: OC Register: Former California First Lady Maria Shriver gives UC Irvine gender-related research on Alzheimer’s disease another boost … Could I have immunity to the COVID-19 virus? As COVID-19 cases spread across the state and nation, demand is growing for blood tests to identify people who may have been exposed to the novel coronavirus and developed antibodies to it. Such antibodies may mean these individuals have at least some immunity to the virus, formally named SARS-CoV2, and… NIH Awards Over $100 Million to Examine Biomarkers of Alzheimer’s Disease in Adults with Down Syndrome Congratulations to UCI MIND investigators, Drs….

Read More

The 90+ Study on 60 Minutes this Sunday

By Commentary, In the News

The 90+ Study, co-led by UCI MIND faculty members Drs. Claudia Kawas and Maria Corrada, will be featured in the show “60 Minutes” this Sunday, November 22 on CBS. The episode will be a follow-up of the study participants who were featured on the show six years ago and an update on research findings since then. Learn more about the feature in the articles below: Lesley Stahl follows up with nonagenarians from landmark study on aging Is there a secret to living well into your 90s? Related posts: VIDEO: Staying Aware of Your Memory and Your Brain with Dr. Frank…

Read More

Cartographers of the brain

By Carousel Slider, Commentary, In the News

Contributed by UCI News: UCI’s Center for Neural Circuit Mapping is redrawing our understanding of mechanisms underlying several common disorders by Ian Anzlowar, UCI | November 18, 2020 Thanks to Xiangmin Xu and his team at the UCI School of Medicine’s Center for Neural Circuit Mapping, lazy eye, Alzheimer’s and other neurological diseases could become a thing of the past. Opened earlier this year, the unit focuses on basic neuroscience research, advancing knowledge of the brain by defining mechanisms and pathways that underlie neurodevelopmental, neuropsychiatric and neurodegenerative disorders. “Our 30 to 40 investigators can join forces to tackle large-scale research…

Read More

Deep Sleep Protects Against Alzheimer’s Disease, Growing Evidence Shows

By Commentary

Commentary on NPR article, contributed by Bryce Mander, PhD Numerous studies now show that multiple forms of sleep disturbance increase risk for developing dementia. Emerging work continues to demonstrate that the way in which the brain expresses sleep may be tied to how much Alzheimer’s disease (AD) pathology there is in the brain even prior to AD symptom onset. Both sleep restriction and suppression of high amplitude, low frequency brain waves – called slow waves – during deep sleep increase beta amyloid and tau, the two hallmark pathologies of AD. It is unknown how this occurs, though there is evidence of two potential mechanisms: increased production of AD…

Read More

UCI C2C Registry now live in multiple languages

By Commentary, In the News

In 2016, UCI MIND launched a local recruitment registry – the UCI Consent-to-Contact (C2C) Registry – to raise awareness of research participation opportunities at UCI (c2c.uci.edu). We are excited to announce that this fall, the UCI C2C went live in Spanish, Korean, Chinese, and Vietnamese to allow more people to access this online tool. Together with our diverse community, we will improve our understanding of Alzheimer’s disease and related dementias in diverse populations and find solutions for people of all backgrounds. To learn more about enrolling in C2C, visit c2c.uci.edu > To read more in our latest newsletter, click here > Related posts: VIDEO:…

Read More

MIND Matters | Quarterly Newsletter | Fall 2020

By Commentary, Community Events, COVID-19, In the News, Participants

Message from the Director   Dear Friends of UCI MIND, As the COVID-19 pandemic continues to impact our lives this fall, the fight to solve Alzheimer’s disease and related dementias (ADRD) must charge forward. This November, the U.S. FDA will convene an advisory committee to assess potential approval of Biogen’s aducanumab, a monoclonal antibody in development for treatment of early AD. We will watch closely as aducanumab could be the first new approved drug for AD since 2005. Regardless of the outcome of the meeting and subsequent FDA decision – anticipated in March 2021 – this represents a milestone for…

Read More

FDA Advisory Panel Recommends Against Approval of Aducanumab for the Treatment of Alzheimer’s Disease

By Commentary, In the News

Many of us listened intently today as the US Food and Drug Administration convened a panel of expert members of an advisory committee to review the submitted materials for potential approval of Biogen’s candidate treatment for early Alzheimer’s disease, aducanumab. The meeting was notable on many levels. Advocates made clear and compelling demonstrations of why new therapies are so desperately needed for this disease. The experts, however, were equally clear that the available data from a still limited number of studies, only one of which was actually positive, do not meet the current standards for drug approval in the United…

Read More